Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2006

View Archived Issues

Medicure makes productive start to FY2007

Genzyme offers progress report for third quarter

Taisho presents prodrug of antidepressant and anxiolytic agent MGS-0039

PDL BioPharma and ECCO collaborate to support visilizumab program

Adventrx licenses ANX-211 to Theragenex

Starpharma completes acquisition of Dendritic Nanotechnologies

Zenyth shareholders approved CSL acquisition proposal

Lytix seeks to outlicense SAMPs

Connetics and Stiefel Laboratories sign definitive merger agreement

Pivotal study of Efaproxyn cleared to continue to final analysis

ChondroGene changes name to GeneNews

AV-412 begins clinical trials

Second phase III trial of Mozobil completes enrollment

Phase I study of GlycoPEG-GCSF cleared to begin in Western Europe

Data on phenylalanine reduction with sapropterin reported

Losartan may benefit Duchenne muscular dystrophy, Marfan syndrome patients

Two phase III studies of MK-0518 in HIV infection under way

Abbott profiles novel 5-HT5A receptor antagonist candidates

Recent patents report novel therapeutic agents for Alzheimer's disease

Novel agents for HIV infection patented

Recent patents cover possible novel treatment options for diabetes and associated disorders

Inhibition of oncogenic FoxM1 by siomycin A: A new anticancer strategy

Pfizer presents novel PDE10 inhibitors as potential antipsychotics

Preclinical data support repositioning propranolol from hypertension to Alzheimer's disease

NPY Y5 antagonist radioligands from Merck & Co., useful to characterize Y5 brain distribution

Seroquel approved for depressive episodes associated with bipolar disorder

Noxafil approved for treatment of oropharyngeal candidiasis

New Nexium formulation approved by FDA

Requip approved in Japan for Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...